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Abstract
In recent decades, both asthma prevalence and incidence have been increasing worldwide, not only due to the
genetic background, but mainly because of the effect of a wide number of environmental and lifestyle risk factors.
In many countries noncommunicable diseases, like asthma, are not yet considered a healthcare priority. This review
will analyze and discuss disparities in asthma management in several countries and regions, such as access to
healthcare human resources and medications, due to limited financial capacity to develop strategies to control and
prevent this chronic disease.
This review tries to explore the social and economic burden of asthma impact on society. Although asthma is
generally accepted as a costly illness, the total costs to society (direct, indirect and intangible asthma costs) are
difficult to estimate, mainly due to different disease definitions and characterizations but also to the use of different
methodologies to assess the asthma socio-economic impact in different societies.
The asthma costs are very variables from country to country, however we can estimate that a mean cost per patient
per year, including all asthmatics (intermittent, mild, moderate and severe asthma) in Europe is $USD 1,900, which
seems lower than USA, estimated mean $USD 3,100.
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Background
In recent decades, both asthma prevalence and incidence
have been increasing worldwide, not only due to the
genetic background, but mainly to the effect of a wide
number of environmental risk factors, many of which in-
cluded under the umbrella of “modern lifestyle”. How-
ever, the worldwide economic globalization could also
have contributed to a significant increase in the asthma
burden, even in developing countries that presented a
low disease prevalence in the recent past [1, 2].
In this review, we will analyze and discuss some items
regarding the socio-economic aspects of asthma, such as:
 The burden of asthma
 Asthma as a global disease
 Asthma mortality
 Asthma characterization
 Asthma co-morbidities
 Global asthma cost (direct and indirect)
 Social impact
The burden of asthma
Asthma is primarily a chronic inflammatory disease that
tends to present as a lifelong condition, with different
severity degrees throughout the asthma patient’s life [1, 2].
Described since Hippocrates, asthma affects people from
all age groups and presents its peak incidence in child-
hood. Recent data from the general population showed
that in children up to 5 years old, the overall asthma inci-
dence rate was 23/1,000 children per year; this incidence
rate decreased among youth aged 12–17 years old to 4,4/
1,000/year. Adult females had 1.8 times greater asthma
incidence than adult males (4.9/1000 vs. 2.8/1000, re-
spectively) [3].
In the United States of America (USA), per the Na-
tional Health Interview Survey (NHIS)-2012, about 40
million people suffered from lifetime asthma (13% of the
USA population) and 26 million people (8%) suffered
from current asthma [4]. The lifetime asthma prevalence
in different countries was estimated to range from 1 to
18% of the general population [5].
So, worldwide, it is estimated that nowadays more
than 300 million people have asthma [1]. In 2025, we
will probably have more 100 million asthma patients [5].
However, this may be an underestimation as asthma
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underdiagnosis is well-known [1]. Moreover, estimates of
asthma prevalence are highly variable per the different
methodologies used to collect and report data (e.g. dif-
ferent asthma definitions, different outcomes, among
others). In fact, the best combination of questions to
define asthma in epidemiological studies is not known.
A recent review summarized the operational asthma
definitions used in prevalence studies and evaluated
how asthma prevalence estimates vary depending on the
definition used [6]. In the literature, lifetime asthma, diag-
nosed asthma and current asthma were defined in 8, 12
and 29 different ways, respectively. By applying definitions
of current asthma to data from the 2010 Portuguese
National Asthma Survey (INAsma) [7] and the 2005-2006
National Health and Nutrition Examination Survey
(NHANES) [8], the prevalence ranged between 5.3 to
24.4% and 1.1 to 17.2%, respectively. The authors con-
cluded that epidemiological asthma definitions can lead
to highly variable estimates of asthma prevalence and a
standardized operational definition is needed [6].
Asthma is associated with a high disease burden. In
children aged less than 5 years old and as well as in the
mid-childhood ages, 5–14 years old there is a high preva-
lence worldwide with a significant relevance and even in
these age groups is consider as one of the top chronic
conditions causing disability-adjusted life years (DALYs).
There are striking global variations in the prevalence of
asthma symptoms in children, with an up to 13-fold differ-
ence between countries [1, 5]. Although asthma has a high
burden in children, the relative importance of asthma
impact increases with age and is particularly apparent
in elderly, especially in women [9]. In Korea, for instance,
although the costs for children accounted for the largest
proportion of the total, the per capita cost was highest
among patients with ≥50 years old [10].
Asthma symptoms are usually more common in
high-income countries (HICs); however, some low- and
middle-income countries (LMICs) also have a high preva-
lence [1, 5]. In fact, the highest prevalence of severe
asthma symptoms among children with wheeze in the past
12 months is found in LMICs [11]. From the 1990s to the
2000s, asthma symptoms became more common in some
high-prevalence centers in HICs; however, in many HICs,
the prevalence remained stable or even decreased [12].
Concurrently, many LMICs with large populations showed
prevalence increases, suggesting that the overall world
asthma burden is increasing, while global disparities in
asthma prevalence are decreasing ([11, 12].
Asthma can be deemed a significant public health
problem, which often requires the use of emergency care,
sometimes including hospital admission, and is responsible
for a high number of missed school and/or work days;
moreover, it can cause early permanent disability and pre-
mature death [5, 11]. In fact, asthma can be associated with
significant limitations on physical, social and professional/
student aspects of the life of those who suffer from this
disease, namely when it is not controlled [1, 5]. Overall,
asthma-related costs are very high [12].
Recent data from USA clearly showed that medical ex-
penditures attributable to asthma were significantly higher
for those with markers of uncontrolled disease when com-
pared with medical expenditures of those who did not have
asthma. Moreover, individuals with uncontrolled asthma,
when compared with those without asthma, had up to
4.6-fold greater frequency of hospitalizations (p < 0.01),
up to 1.8-fold higher number of emergency department
visits (p < 0.01) and lower productivity (more likely to
be unemployed, more days absent from work and more
activity limitations; p < 0.01); however, hospitalizations
rate of individuals with controlled asthma were not dif-
ferent from heathy subjects [13]. Similar results were
found in several other surveys, namely in European
asthmatic adults [14]. As the cost of asthma drastically
increases as disease control decreases, substantial cost
savings could be obtained through the proper manage-
ment of asthmatic patients [1, 13].
Asthma as a global disease
Asthma has clearly shown to be a global disease, however
in last two decades was defined as a real public health
problem affecting countries from all over the world and
population of all age groups [1, 5, 15]. However, there are
differences among countries, with rates significantly above
the average, for example, in some native English-speaking
countries (e.g.: UK, Australia and New Zealand) and, in
contrast, much lower-than-average prevalence rates in
some African and Asian countries [1, 15, 16].
Upon the first epidemiological publications on asthma,
it was noted that asthma prevalence was higher in social
classes with a high or very high annual income and that
asthma severity was higher among the most disadvantaged.
However, the latest epidemiological data from Africa, Latin
America and Asia, showed that, in areas with low economic
development, asthma prevalence has been increasing
[1, 5, 16]. Although there could be several explanations,
the development of larger cities, with consequent reduc-
tion of rural areas, may have played a role. With most the
world population living in urban areas, the environmental
conditions as the lifestyle changes have certainly influ-
enced the asthma prevalence rate increase [2, 5].
Consequently, it can be said that asthma, worldwide, is
“globalized and affect all countries as a public health
problem”.
Asthma mortality
The worldwide number of asthma deaths is about 180,000
per year, with a wide variation between continents, re-
gions, age and economic groups [2, 16].
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In the last decades, there was a significant reduction
in asthma-related mortality, while, with an aging popula-
tion, chronic respiratory diseases are becoming a more
prominent cause of disability [17]. In fact, with the
spread of new treatment guidelines, that emphasize the
use of preventive anti-inflammatory drugs (e.g.: inhaled
corticosteroids) to control the disease, mortality due to
asthma has fallen substantially in most high-income
areas; the USA is an exception, however, as no signifi-
cant reduction on asthma mortality was seen in the last
decades, especially in asthma patients with low-income
[1, 2, 5, 17, 18]. Both premature deaths and permanent
disabilities are costly, especially for those countries where
these situations are more common [2, 5].
Asthma characterization
Asthma is a complex chronic disease that presents acute
exacerbation periods with dyspnea and bronchospasm
which are usually reversible by bronchodilators [1]. Con-
sidering disease manifestations, patients with asthma can
have both short-term treatment for asthma exacerbations
and long-term treatment to obtain and maintain asthma
control. Long-term treatment is crucial to reduce future
risks, namely asthma attacks and lung function deterior-
ation. Also, atopic sensitization and comorbidities are
present in a large percentage of asthmatics. Indoor and
outdoor allergies are very common and many asthmatics
have more than one type of allergic sensitization.
Emergency care for the treatment of asthma attacks
is frequently, and sometimes almost exclusively, used
by many asthma patients [2, 5]. This frequent need for
asthma-related unscheduled medical observations has
multiple identified causes, namely reduced compliance or
non-compliance to asthma management, severe asthma
that is not responsive to the prescribed treatment, eco-
nomic disadvantage that prevents patients from buying
controller medication, insufficient resources in terms of
outpatient health professionals and/or equipment and
patient exposure to trigger factors (e.g.: acute respiratory
infections, environmental and/or occupational irritants/al-
lergens and tobacco consumption and/or passive expos-
ure, among others). Usually, even patients with very
frequent use of emergency care show low asthma-related
hospitalization rate. However, in individuals with <5 years
old and >65 years old, the number of hospitalizations
has been increasing in the last two decades, especially
in areas/regions with low socioeconomic development
[18–20].
Asthma co-morbidities
The most common co-morbidities related to asthma are
rhinitis/rhinosinusitis, gastroesophageal reflux disease, sleep
apnea, psychiatric diseases and cardiac diseases. It is esti-
mated that more than 60% of asthmatics also have allergic
rhinitis and that at least 10% have chronic sinusitis. The
prevalence of other co-morbidities is lower, and it is esti-
mated that together they do not exceed 20 to 30% in chil-
dren and young adults. In elderly, however, co-morbidities
are more frequent (>50%). The treatment and control of
these co-morbidities, in many asthmatic patients, is essen-
tial to achieve asthma control, while keeping the focus ex-
clusively on asthma symptoms might lead to persistent lack
of disease control [1]. The concurrent treatment of asthma
and its co-morbidities increases the direct costs of treat-
ment; however, the lack of asthma control associated with
deficient treatment leads to frequent emergency visits and
hospital admissions, mainly in elderly people, and increases
total costs of asthma management [1, 2, 5].
Global asthma costs
Disease-related cost is usually classified into direct, in-
direct and intangible costs.
The studies of the economic effect of asthma have been
principally of 2 kinds: those using population-based sam-
pling frames or administrative databases to provide cost
estimates for entire regions or nations, and those using
clinical-based sampling frames [21]. The population-based
studies have greater generalizability, whereas the clinical-
based studies have greater diagnostic certainty and,
frequently, data on disease severity that is particularly
relevant to asthma costs.
Direct cost include asthma management (e.g. visits to
emergency services; hospital admissions; medications,
including all types of medications, such as over-the-
counter and alternative medicines; outpatient visits, in-
cluding all human resources involved, such as doctors,
nurses, paramedics, psychologists…), complementary in-
vestigations or treatments (e.g. imaging, skin and blood
tests, lung function tests, pulmonary rehabilitation…)
and other costs (e.g. domestic or professional preventive
measures, assistance in home care, transportation to
medical visits…).
Indirect costs include work-related losses (e.g. tempor-
ary disability in terms of partial or total lost-days; early
disability; permanent disability…) and early mortality.
Finally, intangible costs are those related with unquanti-
fiable losses, such as the decrease in quality of life, in-
creases in pain or suffering, limitation of physical activities
and job changes. These costs, unfortunately, are not yet
systematically referenced in the literature on asthma costs.
A lot of studies reported data on asthma costs, either
at the individual patient, or on the society (regional or
country level), and it can be an average annual per-
asthmatic cost of about $USD 5,000, being much higher
in severe asthmatics [21].
However, only in 2009 was published the first systematic
review of the literature regarding the economic burden of
asthma. The authors included 68 studies and found that
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hospitalization and medications were the most important
drivers of direct costs; work and school loss accounted for
the greatest percentage of indirect costs. Globally, asthma
costs were increasing, closely correlated with comorbidi-
ties, age and asthma severity [22]. A recent estimate of
total annual asthma costs in the USA, stated that they
were growing fast and steadily, from $USD 12 billion in
1994 to $USD 56 billion in 2011 [23].
The total asthma costs have significant differences be-
tween countries, depending of several factors:
1 - Country Gross Domestic Product (GDP)
2 - Geographic and demographic status
3 - Type of health system (public and/or private)
3.1 - Organization of health services (health
authorities, hospitals, clinics)
3.2 - Primary care (developed vs non-developed
countries)
3.3 - Hospital network per region in the country
3.4 - Private clinics (complementary or fundamentals)
4 - Financial resources on Public Health
4.1 - Prevention and promotion of quality of life
4.2 - Links with organizations such as schools,
pharmaceutical industry
4.3 - Rehabilitation of asthma patients and their work
5 - Relationships between governments and
pharmaceutical industries regarding medications.
6 - Methods of data collection
According to the World Health Organization, in 2004,
the world total asthma costs probably exceeded those of
tuberculosis and HIV/AIDS combined [24].
The relation between direct and indirect asthma costs
is variable and depends on country and type of study.
Most asthma studies performed in the last 2 decades
showed that direct costs are higher than indirect costs.
Usually, directs costs contribute to 50 to 80% of the total
costs [10, 21, 25–31].
Direct costs
Direct cost includes asthma management and related to:
1.1 - Visits to emergency services
1.2 - Hospital admissions
1.3 - Medications (including all types of medications
that the patient takes including OTC or use of
alternative medicines
1.4 - Outpatient visits (includes all human resources
involved, such as doctors, nurses, paramedics,
psychologists, etc.)
1.5 - Complementary investigations or treatment
(imaging, blood test, lung function tests and
rehabilitation)
1.6 Other costs (domestic or professional preventive
measures, assistance in home care, transportation to
medical visits, etc.
In many countries, noncommunicable diseases, like
asthma, are not yet healthcare priorities, which can lead
to limited access to regular, preventive, care, both in what
refers to human resources and medications. Moreover,
there may be limited financial capacity to develop strategies
to control and prevent this chronic disease. Therefore, in
this situation, many asthmatic patients treat their asthma
exclusively, or almost exclusively, on emergency rooms or
during hospital admissions. One decade ago, few were the
countries with a national asthma program focused on dis-
ease control, as it was the case in the USA, and in Europe
in countries like Finland, France or Portugal. Beyond soci-
etal factors, such as differences in presence and type of
health insurance and systems of care, there are also patient
factors, like literacy, knowledge, beliefs, attitudes and lan-
guage that may influence asthma costs [2].
Expenditures with asthma among USA individuals
(aged 5–56 years) were compared using the 1996 to
1998 and the 2004 to 2006 Medical Expenditure Panel
Surveys [32]. Direct expenditures (medications, inpatient,
outpatient, and emergency services) and changes in prod-
uctivity (indirect cost) were compared over this time
frame. Mean annual per capita healthcare expenditures
significantly increased between 1996-1998 and 2004-2006
($3802 vs $5322), annual medication expenditures dou-
bled from $974 to $2010 per person and outpatient
visit expenditures increased from $861 to $1174, while
hospitalization and emergency department visit expen-
ditures were similar over the same period. The authors
concluded that the total direct expenditures in individ-
uals with asthma were largely driven by an increase in
spending on medications [32].
Another study reporting data from Europe in a real-
world evaluation of the economic cost of persistent
asthma among adults per the degree of disease control
(462 patients aged 30–54 years from 11 European coun-
tries, examined in clinical settings in the European Com-
munity Respiratory Health Survey II, 1999 to 2002),
found that the mean total cost per patient was €1,583
and, in this study, this was largely driven by indirect costs
(62.5%). The expected total cost in the population aged
30–54 years of the 11 European countries was €4.3 billion
(€19.3 billion when extended to the whole European
population aged from 15 to 64 years). The mean total cost
per patient ranged from €509 (controlled asthma) to
€2,281 (uncontrolled disease). Chronic cough or phlegm
and having a high BMI significantly increased the individ-
ual total cost [14].
In Fig. 1 we present an estimate of the annual asthma
cost per patient in Europe using the Purchasing Power
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Parity (PPP) technique to make comparisons among
costs in countries with different Gross National Product
(GNP) and different prices on human resources, drugs
and hospitalizations [33].
Within the direct costs, in some regions, like USA
and several countries from Central/South America and
Southeast Asia, the expenses with hospital inpatient care
represent the major component [1, 22, 25]. Nevertheless,
in Europe and Korea it is the outpatient medication and
human resources that are responsible for most of the
direct costs [10, 28, 34, 35].
In USA 2012 data from the National Hospital Ambula-
tory Medical Care Survey (NHAMCS), found that, annu-
ally, 20% of asthmatics, from those who need emergency
service visits, have at least one hospital admission with
an average of 3.6 days of hospitalization [23].
Regarding asthma-related hospitalizations, children and
adolescents have a prevalence that is at least twice that of
adults. In children aged 0–4 years, asthma-related hospi-
talizations are particularly frequent. Asthma is one of the
most common chronic diseases in childhood and one of
the main causes of hospitalizations [2].
The expenses related to hospital inpatient care are
variable. Some studies have found higher costs in private
versus public or non-profit hospitals. However, the dif-
ference is only around 20 to 30% of the cost [36–39].
In the last decade, many generic drugs to treat asthma
become available, which were cheaper than brand drugs.
In Europe, the prices of inhaled steroids (combined or
not with long-acting bronchodilators) are variable from
country to country. Most patients with persistent asthma
need daily medication, have yearly differences in total
medication cost among European countries.
Human resources and complementary expenses in
outpatient settings, such as offices, clinics or hospital
ambulatory, usually contribute from 50 to 65% of total
direct costs. This percentage depends on the health sys-
tem, public versus private and insurance coverage.
In Europe, for instance, there are several types of health
public facility organization. We can divide them into 2
strategies: one related to “reliance on market mechanisms
in service provision” and another in “mostly public
provision and public insurance”. The interaction with pa-
tient payment and/or reimbursement makes a significant
Fig. 1 Annual cost of asthma per patient in Europe
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difference on the total direct cost supported by asthma
patients and their families [40].
In UK, where there is a gate-keeping system with an
ample choice of providers for users and a restrict budget
constraint, asthma places a high burden on the primary
health care system, with over 4 million consultations
each year. An average primary care organisation in the
UK including 330,000 people can expect to treat 25,000
people with asthma, with over 400 patients with asthma
admitted to hospital. The total cost of asthma in UK has
been estimated to be about $5 billion. This includes the
cost of about $1 billion to the public health service. It is
estimated that 50% of all annual healthcare costs with
asthma come from the most severe asthmatic population
(~20% of total individuals with asthma). About 20 million
working-days are lost due to asthma each year [33].
In a cohort study of children and adolescents, followed
during 20 years, it was found that patients with moderate
and severe asthma had an average of 7.4 consultations per
year, 3.4-fold higher than the general population needs in
term of medical visits per year. Individuals with mild per-
sistent asthma only needed an average of 3.7 medical visits
per year; however, even this value is higher than the one
found in the non-asthmatic population (2.1 visits). More-
over, individuals with asthma had an average of 0.7 visits
per year to emergency rooms [41].
Indirect costs
Indirect costs include:
1.1 Costs related to work
1.1.1 - Temporary disability (partial days, total days)
1.1.2 - Early Disability
1.1.3 - Permanent disability
1.2 - Early mortality
Asthma often generates temporary incapacity for work
and a significant percentage of premature permanent
disability retirements, although mortality rate is low.
The loss of productivity can be partial, with restricted
work days or presentism, or total due to absenteeism
from work. In most patients with asthma attacks who
need home treatment, the average working day absenteeism
is 5.6 days. When hospital admission occur the average
number of working days lost is 13 days, with an average of
4 days of hospital stay [42–44].
Considering data from the Medical Expenditure Panel
Survey in the US, over the years 2002–2007, the value of
additional days lost attributable to asthma per year was
approximately $301 for each worker and $93 for each
student. In 2007, the total incremental cost of asthma to
society was $56 billion, with productivity losses due to
morbidity accounting for $3.8 billion and productivity
losses due to mortality accounting for $2.1 billion [45].
Missed school and work days decreased between the 2
periods (9.2 days in 1996-1998 vs 6.4 days in 2004-
2006). In the period from 2000 to 2009 it was found, in
the same surveys, that although medical costs for pa-
tients with asthma increased or remained stable across
all age groups over the 10-year period, outcomes did not
improve; this stresses the need to reflect about the rela-
tion between asthma costs and outcomes [46].
An asthmatic child with an exacerbation of his/her
symptoms, usually, loses from 3 to 5 school days and at
least one of the parents/caregivers loses the same work-
ing time [2, 47, 48]. Therefore, children with asthma
have more indirect costs than older asthmatics, as the
parents missed work-days sum to the other expenses as
an indirect cost.
Severe asthma has an estimated prevalence of up to
8% within asthmatics. Some of these patients, especially
after 50 years old, can have limitations on their work
and other activities due to asthma symptoms and lung
function losses [49, 50]. Severe asthma, despite being
less prevalent than other asthma severity classes (Fig. 2),
is responsible for a large part of asthma-related costs. So,
asthma cost is growing, probably more than expected,
with asthma severity (Fig. 3).
Individuals with asthma can have restricted working
days or, in many cases, need for temporary free days for
rehabilitation of an asthma exacerbation; nevertheless,
some of these patients need retirement or removal from
their work due to incapacity to have a normal productivity.
This contributes significantly to indirect costs and reflects
on DALYs, as a measure of overall disease burden,
expressed as the number of years lost due to ill-health,
disability or early death. Worldwide, asthma accounts
for about 1% of all DALYs lost, which simultaneously
reflects high prevalence and severity [51].
Early death due to asthma is also very important. An
evaluation performed by WHO refers that, in Europe,
asthma is responsible for approximately 0.4% of all
deaths (43,000 persons) and 1% of the global disease
burden, equivalent to 1,358,000 DALYs asthma related
death-rate [40].
Asthma-related death rate and DALYs are widely dif-
ferent among European countries (Fig. 4) [51].
Average life expectancy of asthmatics is lower than
that of the general population. However, when interpreting
these comparisons, we should consider that even within
the most developed countries in the world, life expectancy
at birth in men differs among European Union state
members [52].
Social impact
Socio-economic impact of a disease assessment focuses
on evaluating the impacts development has on community
social and economic well-being. Development impacts are
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Fig. 3 Asthma total cost by severity in Europe
Fig. 2 Total asthmatics in Europe by severity
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generally evaluated in terms of changes in community re-
sources, housing, employment and income, market effects,
public services, and qualities of the community.
Considering this social impact related asthma costs,
under economic point of view that there are significant
differences among prices per country, depending of sev-
eral factors:
1 - Country Gross Domestic Product (GDP)
2 - Geographic and demographic status
3 - Type of health system (Public versus Private)
3.1 - Organization of health services (health
authorities, hospitals, clinics)
3.2 - Primary care (developed vs non-developed)
3.3 - Hospital network per region in the country
3.4 - Private clinics (complementary or fundamentals)
4 - Financial resources on Public health
4.1 - Prevention and Promotion in quality of life
4.2 - Links with organizations such as schools,
pharmaceutical industry, etc.
4.3 - Rehabilitation of asthma patients and their work
5 - Government and pharmaceutical industry
relationship regarding medication, mainly the use of
generic drugs to asthma treatment.
6 - Methodology used to collect data
In general, in the 28 countries from the European
Community, it was estimated that there are more than
30 million of asthmatics (mean asthma prevalence of
7%), that account for a total expense of more than €20
billion in the European population aged from 15 to
64 years [33].
The asthma costs are very variables from country to
country, however we can estimate that a mean cost per
patient per year, including all asthmatics instead of their
severity (intermittent, mild, moderate and severe asthma)
in Europe is $USD 1,900 [14, 33]. However, in USA,
estimated mean cost per patient and per year is $USD
3,100 [8, 19, 21, 23, 32].
The assessment of asthma burden is a challenge.
Even when using similar research protocols, reports
on asthma prevalence and disease characterization (e.g.
severity) have shown huge variations within and among
countries.
Asthma prevalence and severity increased around the
world, particularly in underprivileged populations. There
are underserved individuals living in large urban centers
of high-income countries with limited access to health
care. In various large cities of low and middle-income
countries, asthma prevalence is nowadays very high and
most of the population cannot afford paying for the proper
treatment of persistent asthma. These unfavorable scenarios
lead to a situation in which dozens of millions of human
beings suffering from asthma, from all age groups, cannot
afford the right to breathe well [51, 53].
Despite significant progress in health outcomes over
the last two to three decades, inequities continue to in-
crease and there are gross disparities between countries
at all levels of health expenditure [2].
Low-income populations, poor minorities and children
living in inner cities, suffer a disproportionately higher
morbidity and mortality because of asthma. In poor
households, relatively small costs related with health
promotion and disease control can be disastrous and as-
sumed as catastrophic expenditures.
In children, the increasing number of hospital admis-
sions due to asthma attacks or exacerbations, namely
those related with respiratory infections, is still high,
both in USA and in Europe. These contribute to increas-
ing direct costs in hospital and medication as well as in-
direct costs for missing working days. In schoolchildren,
there will be lost school days, which lead to limitation
on study performance, with consequent psychological
effects in asthmatic children.
Fig. 4 Mortality death rate and DALY rate per 100.000 inhabitants, age- standardized
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In elderly asthmatics with several comorbidities, ex-
acerbation of asthma symptoms is frequent, leading to
increased medication need, increased outpatient hospital
visits and hospital admissions, and contributing to an
increase of asthma costs to the patient and society. The
treatment of comorbidities can reach costs that are like
asthma treatment expenses.
Management programs focused on treatment regimens
which have been shown to reduce hospital admissions
represent a cost-effective strategy for the management of
asthma. The implementation of these programs within
some developed countries, being the Finnish asthma
program [54] one of the best known examples, showed a
dramatic reduction in mortality and severity in parallel
with costs reduction. This must also be implemented in
low- and middle-income regions [1, 53].
The economic burden of asthma disparities can be de-
creased with access to preventive care, early treatment
and the use of primary care health providers instead of
emergency departments. There are some generic barriers
to achieve a better health, which include poverty, poor
education, lack of sanitation and poor infrastructure;
and some environmental barriers that include tobacco
smoking, pollution and poor nutrition. These needs to be
corrected by health regional or country programs [2, 4, 11].
Moreover, the organization of health care services has in-
herent barriers in terms of geography, the type and training
of the professionals that are needed, the type of health care
to provide (public vs. private), the usual tendency for care
to be “acute” rather than “routine” and the availability and
use of medications.
In low income countries, asthma guidelines are strikingly
hard to implement, and more research is needed to evalu-
ate whether therapeutic trials conducted in high income
countries, and resultant recommendations, are equally ap-
plicable to low income regions. Even in medium-or high-
income countries are difficulties to implement national
asthma plans.
Even in medium- or high-income countries, asthma
burden is not seen as a health public problem and it is
often poorly known.
The disease burden and health priorities differ from
one country or region to another, but asthma, as other
noncommunicable chronic respiratory diseases, must be
in the agenda of each national authority [1, 53].
Larger studies, with comprehensive data collection,
should be undertaken to make a better assessment of
the magnitude of the problem and to provide data for a
better-informed health policy. As an example, in the UK,
an initiative aiming to provide data on previously iden-
tified gaps on asthma costs was launched; its ultimate
vision is to contribute to obtain valid data that allows
policy changes leading to the provision of more cost-
effective care [55].
Conclusions
Worldwide, in the last decades, asthma prevalence has
been increasing. Asthma tends to be a lifelong condition
with a high burden. The asthmatic patients often use
emergency care, sometimes requiring hospital admission,
and have a high number of school days missed and
workdays lost. In addition, it can cause early permanent
disability and premature death.
The economic burden of asthma is an important
measure of its effect on society. Although it is recognized
that asthma is a costly illness, the total cost of asthma to
society has not been estimated in most countries. Asthma-
related costs are high and should be systematically moni-
tored using standardized methods; they should consider
the natural history of the disease, incidence and preva-
lence trends, environmental impact, comorbidities, quality
of life, ageing of the population, the effect of guidelines
implementation and differences in national health systems
and income levels.
In the last decades, several guidelines, both global (e.g.
GINA) and at national/regional levels, were created trying
to delineate better diagnosis and treatment strategies,
emphasizing that achieving clinical control and redu-
cing future risk should be the primary targets of asthma
management; moreover, they propose approaches that
promote a more adequate use of healthcare resources
and should present as cost-effective strategies. However,
the estimated costs of asthma can still be considered
substantial, stressing the need for more comprehensive
approaches that can be fully implemented in different
settings.
We believe that management programs represent a
cost-effective strategy for the control of asthma at a
country level, and that the economic burden of asthma
can be decreased with improved access to preventive
care and early treatment.
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